Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
33.62
+1.21 (3.73%)
At close: Apr 9, 2026, 4:00 PM EDT
33.62
0.00 (0.00%)
After-hours: Apr 9, 2026, 4:03 PM EDT
Celldex Therapeutics Employees
Celldex Therapeutics had 198 employees as of December 31, 2025. The number of employees increased by 12 or 6.45% compared to the previous year.
Employees
198
Change (1Y)
12
Growth (1Y)
6.45%
Revenue / Employee
$7,803
Profits / Employee
-$1,306,854
Market Cap
2.63B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 198 | 12 | 6.45% | 198 | 0 |
| Dec 31, 2024 | 186 | 26 | 16.25% | 186 | 0 |
| Dec 31, 2023 | 160 | 12 | 8.11% | 160 | 0 |
| Dec 31, 2022 | 148 | 14 | 10.45% | 148 | 0 |
| Dec 31, 2021 | 134 | 9 | 7.20% | 132 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Ascentage Pharma Group International | 767 |
| ADMA Biologics | 647 |
| Beam Therapeutics | 511 |
| Relay Therapeutics | 192 |
| Soleno Therapeutics | 182 |
| Immunome | 177 |
| Disc Medicine | 155 |
CLDX News
- 3 days ago - Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 7 days ago - Celldex Announces Pricing of $300 Million Public Offering of Common Stock - GlobeNewsWire
- 8 days ago - Celldex Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 13 days ago - Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 - GlobeNewsWire
- 5 weeks ago - Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 - GlobeNewsWire
- 6 weeks ago - Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria - GlobeNewsWire
- 6 weeks ago - Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile - GlobeNewsWire